Keywords: EMEA, Oganon, Recordati, Axxonis, Antigenics, Teva, Genzyme, Roche, GSK, Novartis
Meeting highlights from Europe’s CHMP November 16-19, 2009
Article | 23 November 2009
Following its November 16-19 meetings, the European Medicines Agency (EMEA) says it has reviewed further data on the centrally authorized pandemic vaccines, Celvapan (from Baxter International), Focetria (from Novartis) and Pandemrix (from GlaxoSmithKline). The Agency has reaffirmed that they have a positive balance of benefits and risks in the context of the current H1N1 infuenza pandemic.
< Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
